miR-9和miR-195-3p在原发性肝癌诊断中的应用及其在介入治疗前后的变化  

Application of miR-9 and miR-195-3p in the diagnosis of primary hepatic carcinoma and their changes before and after interventional therapy

作　　者：张冬茜 张海光[2] 张晓茹 郑璇 韩素桂[1] 李颖[1] 郝春海 Zhang Dongqian;Zhang Haiguang;Zhang Xiaoru;Zheng Xuan;Han Sugui;Li Ying;Hao Chunhai(Department of Nuclear Medicine Laboratory,Tangshan People's Hospital,Tangshan 063000,China;Department of Hepatobiliary Surgery,Tangshan People's Hospital,Tangshan 063000,China)

机构地区：[1]唐山市人民医院核医学检验科,唐山063000 [2]唐山市人民医院肝胆外科,唐山063000

出　　处：《国际肿瘤学杂志》2024年第10期627-631,共5页Journal of International Oncology

摘　　要：目的探讨miR-9和miR-195-3p对于原发性肝癌(PHC)的诊断效能,以及介入治疗后miR-9和miR-195-3p水平的变化。方法选取2019年5月—2020年5月于唐山市人民医院就诊的123例PHC患者和30例肝硬化患者分别作为PHC组和肝硬化组,选取同期体检健康的人群50例作为健康组。通过实时荧光定量PCR检测血清miR-9和miR-195-3p水平;分析血清miR-9和miR-195-3p水平与PHC患者临床病理特征的关系;采用受试者操作特征(ROC)曲线分析miR-9和miR-195-3p对PHC的诊断效能;比较经导管肝动脉化疗栓塞(TACE)术治疗前、后PHC患者血清miR-9和miR-195-3p水平变化。结果健康组、肝硬化组、PHC组血清miR-9(0.99±0.10、1.31±0.28、1.68±0.43)和miR-195-3p(0.97±0.10、0.83±0.22、0.63±0.18)水平差异均具有统计学意义(F=69.78,P<0.001;F=74.82,P<0.001),3组间血清miR-9水平依次升高,miR-195-3p水平依次降低(均P<0.05)。不同肿瘤最大径、临床分期及分化程度PHC患者的血清miR-9(t=7.45,P<0.001;t=5.32,P<0.001;t=4.96,P<0.001)和miR-195-3p(t=16.17,P<0.001;t=4.21,P<0.001;t=7.53,P<0.001)水平差异均有统计学意义。ROC曲线分析显示,血清miR-9和miR-195-3p检测联合鉴别诊断肝硬化和PHC的曲线下面积(AUC)为0.919,大于血清miR-9(AUC为0.712,Z=4.38,P<0.001)和miR-195-3p(AUC为0.844,Z=2.04,P=0.042)单独鉴别诊断的AUC。TACE治疗后,患者血清miR-9水平较治疗前下降(1.39±0.21比1.68±0.43,t=14.22,P<0.001),miR-195-3p水平较治疗前上升(0.78±0.22比0.63±0.18,t=14.84,P<0.001)。结论PHC患者血清miR-9水平较肝硬化和健康者升高,miR-195-3p水平较肝硬化和健康者降低,二者联合检测对肝硬化和PHC具有较高的鉴别诊断效能。PHC患者TACE治疗后血清miR-9水平下降、miR-195-3p水平上升。Objective To investigate the diagnostic efficacy of miR-9 and miR-195-3p for primary hepatic carcinoma(PHC),and the changes in miR-9 and miR-195-3p levels after interventional therapy.Methods A total of 123 cases of PHC patients and 30 cases of liver cirrhosis patients attending Tangshan People's Hospital from May 2019 to May 2020 were selected as the PHC group and the liver cirrhosis group,respectively,and 50 people who were physically healthy during the same period were selected as the healthy group.Serum miR-9 and miR-195-3p levels were detected by real-time quantitative PCR.The relationship between serum miR-9 and miR-195-3p levels and clinical-pathological characteristics of PHC patients was analyzed.Receiver operator characteristic(ROC)curve was applied to analyze the diagnostic efficacy of miR-9 and miR-195-3p for PHC.The changes in serum miR-9 and miR-195-3p levels in PHC patients before and after transcatheter arterial chemoembolization(TACE)were compared.Results There were statistically significant differences in serum miR-9(0.99±0.10,1.31±0.28,1.68±0.43)and miR-195-3p(0.97±0.10,0.83±0.22,0.63±0.18)levels among the healthy group,liver cirrhosis group,and PHC group(F=69.78,P<0.001;F=74.82,P<0.001),with serum miR-9 levels increased successively and miR-195-3p levels decreased successively among the three groups(all P<0.05).There were statistically significant differences in serum miR-9(t=7.45,P<0.001;t=5.32,P<0.001;t=4.96,P<0.001)and miR-195-3p(t=16.17,P<0.001;t=4.21,P<0.001;t=7.53,P<0.001)levels in PHC patients with different maximum diameters of tumor,clinical stages and degrees of differentiation.ROC curve analysis showed that the area under the curve(AUC)for the combined differential diagnosis of liver cirrhosis and PHC by serum miR-9 and miR-195-3p testing was 0.919,which was higher than the AUC for the differential diagnosis of serum miR-9(AUC:0.712,Z=4.38,P<0.001)and miR-195-3p(AUC:0.844,Z=2.04,P=0.042)alone.After TACE treatment,serum miR-9 levels decreased(1.39±0.21 vs.1.68±0.43,t=14.22,P<

关 键 词：肝肿瘤 化学栓塞 治疗性 MIR-9 miR-195-3p 

分 类 号：R735.7[医药卫生—肿瘤]